inno.N continues to innovate to create a healthy life for customers.


Heal the World for Better Life

We strive to create a healthy world for a better life for our customers.


The world’s top-tier Biohealth company

A key player in the biohealth industry,

We continue to lead the world towards a better future with innovation.

Innovation Spirit
  • New Move Spirit of first mover creating
    a new trend of pharmaceutical industry
  • Open Innovation Coexistence and collaboration attitude
    continuing open innovation
  • Authentic Humanity Unique sincerity
    for customers’ healthy lives
  • Global Initiative Leading leadership in the future of
    the global pharmaceutical industry
  • Connect Possibility Creative spirit of realizing the possibilities
    of the fourth industrial age




To achieve our mission, ‘Heal the World for Better Life’, we initiated Innovation No.1 inno.N with the goal to develop ground-breaking drugs for the world’s health and in the spirit of creation, innovation, and gratitude towards customers who support us.


Lời chào từ CEO
SeokHee KANG

Để đạt được sứ mệnh ‘Hàn gắn Thế giới vì cuộc sống tươi đẹp hơn’ của Tập đoàn, Chúng tôi sẽ chuyển sang Đổi mới số 1 inno.N để phát triển các loại thuốc trên toàn cầu với tinh thần sáng tạo và không ngừng cải tiến, nhằm đáp lại sự ủng hộ của các Khách hàng toàn cầu.

Lời chào từ CEO


Inno.N was established in 1984 as CJ CheilJedang Pharmaceutical Business Division. With more than 30 years of experience, inno.N has grown to become a leading expert in the pharmaceutical industry.


In 1986, we developed hepatitis prevention vaccine 'Hepaccin-B' with pure domestic technology. We were recognized for our technological capability by mass-producing ‘interferon,’ which was a state-of-the-art basic medicine at that time and 7-ACA, the raw material that requires fine chemical technology.

Bag-type IV Solutions

By producing safe-flex bags for the first time in Korea in 1992, we have brought innovation to the healthcare environment where glass containers used to cause inconvenience in use.


CONDITION, the most popular anti-hangover drink in Korea, has been the indisputable No. 1 brand since 1992 when it first opened the anti-hangover drink market in Korea.


In 1995, inno.N was  the first domestic pharmaceutical company to achieve $ 100 million in exports and led the growth of the industry. With the continuous R&D investment, we launched a renal anemia treatment EPO formulation (product name: EPOKINE) in 1998 and this was the world's third and for the first time in Korea, leading the localization of pharmaceuticals.


In 2006, we successfully strengthened our product portfolio by merge and acquisition of Han-il Pharmaceutical Corp. In 2010, we completed the construction of the Osong plant, the world-class pharmaceutical production facility, giving a leap to become a global pharmaceutical company.

In an effort to build a stronger foundation for a 100-year company that started with CJ Healthcare and advanced into inno.N, we are working to create a more substantial impact on the global high-tech pharmaceutical industry in 2020.

In March 2019, inno.N launched K-CAB Tab.(Ingredient name: tegoprazan), a new drug for Gastroesophageal acid reflux disease in Korea. K-CAB Tab not only yields the most effective among newly developed drugs within the first year of its launch, but it was also exported to 22 other countries: China, Thailand, Indonesia, and 17 nations in Central and South America.

By means of Open Innovation with technologies from both domestic and overseas branches, inno.N accelerates the speed and effectiveness of newly developed drugs while investing in new technologies for the future.

In 2014, inno.N partnered with Pangen to co-develop protein therapeutics. In May 2016, we signed a joint development contract with Y-BioLogics, a new antibody developing company with the purpose of researching dual-target antibodies, anti-cancer immune drugs. Moreover, inno.N is also leading in the country’s pharmaceutical industry owing to our adaptation of innovative technologies advanced technologies from venture companies in the US, Japan, and Europe.